TY  - GEN
AU  - Devogelaer,J P
AU  - Broll,H
AU  - Correa-Rotter,R
AU  - Cumming,D C
AU  - De Deuxchaisnes,C N
AU  - Geusens,P
AU  - Hosking,D
AU  - Jaeger,P
AU  - Kaufman,J M
AU  - Leite,M
AU  - Leon,J
AU  - Liberman,U
AU  - Menkes,C J
AU  - Meunier,P J
AU  - Reid,I
AU  - Rodriguez,J
AU  - Romanowicz,A
AU  - Seeman,E
AU  - Vermeulen,A
AU  - Hirsch,L J
AU  - Lombardi,A
AU  - Plezia,K
AU  - Santora,A C
AU  - Yates,A J
AU  - Yuan,W
TI  - Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
SN  - 8756-3282
PY  - 1997///0529
KW  - Administration, Oral
KW  - Aged
KW  - Aged, 80 and over
KW  - Alendronate
KW  - adverse effects
KW  - Biomarkers
KW  - Bone Density
KW  - drug effects
KW  - Double-Blind Method
KW  - Female
KW  - Hip
KW  - physiopathology
KW  - Humans
KW  - Lumbar Vertebrae
KW  - Middle Aged
KW  - Osteoporosis, Postmenopausal
KW  - drug therapy
N1  - Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/8756-3282(95)00436-x
ER  -